Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Recruiting Phase 1 / 2 Trials for Irinotecan (DB00762)

IndicationStatusPhase
DBCOND0029297 (Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02095132Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid TumorsTreatment